Far East Bio-Tec Co., Ltd.
Far East Bio-Tec Co., Ltd. manufactures and sells organic chlorella, spirulina, and dietary supplements. It also offers nutraceuticals/nutritional supplements, immune booster products, antiviral sprays, and pet supplements. The company was founded in 1976 and is based in Taipei, Taiwan.
Far East Bio-Tec Co., Ltd. (6886) - Total Assets
Latest total assets as of June 2025: NT$688.48 Million TWD
Based on the latest financial reports, Far East Bio-Tec Co., Ltd. (6886) holds total assets worth NT$688.48 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Far East Bio-Tec Co., Ltd. - Total Assets Trend (2020–2024)
This chart illustrates how Far East Bio-Tec Co., Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Far East Bio-Tec Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Far East Bio-Tec Co., Ltd.'s total assets of NT$688.48 Million consist of 62.3% current assets and 37.7% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 42.9% |
| Accounts Receivable | NT$24.78 Million | 3.9% |
| Inventory | NT$74.06 Million | 11.6% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$33.00K | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Far East Bio-Tec Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Far East Bio-Tec Co., Ltd.'s current assets represent 62.3% of total assets in 2024, a decrease from 70.0% in 2020.
- Cash Position: Cash and equivalents constituted 42.9% of total assets in 2024, down from 55.8% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 11.6% of total assets.
Far East Bio-Tec Co., Ltd. Competitors by Total Assets
Key competitors of Far East Bio-Tec Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
General Mills Inc
NYSE:GIS
|
USA | $32.55 Billion |
|
B&G Foods Inc
NYSE:BGS
|
USA | $2.94 Billion |
|
Tangrenshen Group Co Ltd
SHE:002567
|
China | CN¥17.90 Billion |
|
Shenzhen Shenbao Industrial Co Ltd
SHE:000019
|
China | CN¥7.01 Billion |
|
Xiwang Foodstuffs Co Ltd
SHE:000639
|
China | CN¥6.08 Billion |
|
Nanfang Black Sesame Group Co Ltd
SHE:000716
|
China | CN¥4.57 Billion |
|
CNFC Overseas Fishery Co Ltd
SHE:000798
|
China | CN¥5.88 Billion |
|
Henan Shuanghui Investment & Development Co Ltd
SHE:000895
|
China | CN¥40.64 Billion |
Far East Bio-Tec Co., Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Far East Bio-Tec Co., Ltd. generates 0.60x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Far East Bio-Tec Co., Ltd. generates $8.19 in net profit.
Far East Bio-Tec Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.53 | 4.31 | 4.67 |
| Quick Ratio | 3.56 | 3.43 | 3.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$316.66 Million | NT$ 305.37 Million | NT$ 321.33 Million |
Far East Bio-Tec Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between Far East Bio-Tec Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.81 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 12.6% |
| Total Assets | NT$641.30 Million |
| Market Capitalization | $13.64K USD |
Valuation Analysis
Below Book Valuation: The market values Far East Bio-Tec Co., Ltd.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Far East Bio-Tec Co., Ltd.'s assets grew by 12.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Far East Bio-Tec Co., Ltd. (2020–2024)
The table below shows the annual total assets of Far East Bio-Tec Co., Ltd. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$641.30 Million | +12.61% |
| 2023-12-31 | NT$569.49 Million | +4.35% |
| 2022-12-31 | NT$545.75 Million | +17.73% |
| 2021-12-31 | NT$463.57 Million | -4.67% |
| 2020-12-31 | NT$486.27 Million | -- |